Eupalinolide A
CAS No. : 877822-40-7
| Size | Price | Stock |
|---|---|---|
| 5mg | $83 | In-stock |
| 10mg | $130 | In-stock |
| 25mg | $270 | In-stock |
| 50 mg | Get quote | |
| 100 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-N0754 |
| M.Wt: | 462.49 |
| Formula: | C24H30O9 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
Eupalinolide A is a Yes-associated protein (YAP) degrader and HSP70 inducer. Eupalinolide A inhibits osteogenic differentiation of tendon-derived stem cells (TDSCs). Eupalinolide A induces autophagy in hepatocellular carcinoma cells via activating the ROS/ERK signaling pathway. Eupalinolide A protects PAM212 cells from UVB-, Menadione (HY-B0332)-, or heat shock-induced apoptosis. Eupalinolide A alleviates trauma-induced heterotopic ossification (HO) of Achilles tendon and inhibits growth of MHCC97-L and HCCLM3 hepatocellular carcinoma xenograft tumors in mice. Eupalinolide A can be used for the study of traumatic heterotopic ossification of tendons and hepatocellular carcinoma[1][2][3].
In Vitro:Eupalinolide A (1-10 μM, 7-14 d) dose-dependently inhibits osteogenic differentiation of tendon-derived stem cells (TDSCs), as evidenced by decreased alkaline phosphatase (ALP) activity, reduced calcium deposition, downregulated mRNA expression of osteogenic genes (Alp, Col1a1, Osx, Ocn, Opn), and decreased protein levels of OSX and OCN[1].
Eupalinolide A (10 μM) induces YAP degradation via TOLLIP-mediated selective autophagy and Promotes K27-linked polyubiquitination of YAP in HEK293T cells[1].
Eupalinolide A (28 μM, 48 h) reduces BrdU-positive cells and inhibits DNA synthesis in MHCC97-L and HCCLM3 cells via BrdU staining[2].
Eupalinolide A (28 μM, 21 d) decreases colony number and size of MHCC97-L and HCCLM3 cells[2].
Eupalinolide A (7-28 μM, 24-48 h) suppresses migration and reverses EMT of MHCC97-L and HCCLM3 cells[2].
Eupalinolide A (7-28 μM, 48 h) induces G1 phase arrest and autophagy, and increases ROS production in MHCC97-L and HCCLM3 cells[2].
Eupalinolide A (5-10 μg/mL, 24 h) induces HSP70 expression in B16 mouse melanoma cells and PAM212 mouse squamous cell carcinoma cells[3].
Eupalinolide A (2.5-10 μg/mL, 24 h) induces the expression of HSP25, HSP40, and HSP90 (HSP90α) at both protein and mRNA levels in PAM212 cells[3].
Eupalinolide A (5-10 μg/mL, 3 h) promotes phosphorylation and nuclear translocation of HSF1 in PAM212 cells and inhibits the interaction between HSF1 and HSP90[3].
Eupalinolide A (5-10 μg/mL, 24 h) suppresses IBMX (HY-12318)-induced melanin production, tyrosinase activity and downregulates tyrosinase, Tyrp1, and Dct mRNA/protein levels in B16 cells[3].
In Vivo:Eupalinolide A (1-10 μM, local injection, 20 μL/mouse, once weekly for 8 weeks) dose-dependently alleviates trauma-induced heterotopic ossification (HO) of Achilles tendon in mice[1].
Eupalinolide A (30-60 mg/kg, i.p., once daily, 3 weeks) inhibits growth of MHCC97-L and HCCLM3 hepatocellular carcinoma xenograft tumors in female nude mice[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Eupalinolide A
- Cat. No.:
- HY-N0754
- Quantity:
Your information is safe with us.